Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO Study.

Clinical lymphoma, myeloma & leukemia - 1 Aug 2026

Montefusco Vittorio, Cafro Anna Maria, Margiotta-Casaluci Gloria, Mina Roberto, Patriarca Francesca, D'Agostino Mattia, Dalla Palma Anna Benedetta, Rizzi Rita, di Trani Martina, Bertazzoni Paola, Vaudo Gaetano, Petrucci Maria Teresa, Paris Laura, Belotti Angelo, Mancuso Katia, Conticello Concetta, Carlo-Stella Carmelo, Boccadoro Mario

Abstract excerpt

BACKGROUND: Pomalidomide-daratumumab-dexamethasone (DPd) has been shown to be effective in lenalidomide-exposed patients with multiple myeloma (MM). We aimed to evaluate this combination in patients with del(17p), for whom there is no specific treatment. PATIENTS AND METHODS: The phase II DEDALO study enrolled patients with relapsed/refractory (RR)MM, del(17p), and ≤ 3 previous therapy lines including...

Topics

Join the communities discussing this publication.

Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Dexamethasone

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Multiple Myeloma

Neoplasm Recurrence, Local

Tumor Suppressor Protein p53

Source

Identifiers

PMID: 42399199
DOI: 10.1016/j.clml.2026.05.013

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO Study.PMID 42399199Read ↗

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.Semantic proximity Read ↗

Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survivalSemantic proximity Read ↗

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma.Semantic proximity Read ↗

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial resultsSemantic proximity Read ↗

The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.Semantic proximity Read ↗

Minor clone of del(17p) provides a reservoir for relapse in multiple myelomaSemantic proximity Read ↗

Multi-omic and functional screening reveal targetable vulnerabilities in<i>TP53</i>mutated multiple myelomaSemantic proximity Read ↗

Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.Semantic proximity Read ↗

Loss of p53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cellsSemantic proximity Read ↗

Mutations in TP53 are exclusively associated with del(17p) in multiple myelomaSemantic proximity Read ↗

Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.Semantic proximity Read ↗

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.